Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells.

OBJECTIVE To examine the suppressive effect of anti-human Fas monoclonal antibody (mAb) on osteoclastogenesis in rheumatoid arthritis (RA) both in vitro and in vivo. METHODS For in vitro analysis, activated CD4+ T cells derived from peripheral blood mononuclear cells were left untreated or were treated with humanized anti-human Fas mAb (R-125224) and cocultured with human monocytes. On day 12, the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells was counted. For in vivo analysis, tissue derived from human RA pannus was implanted with a slice of dentin subcutaneously in the backs of SCID mice (SCID-HuRAg-pit model). R-125224 was administered intravenously once a week for 3 weeks. The implanted tissue and dentin slice were removed, and the pits formed on the dentin slice were analyzed. RESULTS In vitro, coculture of activated CD4+ T cells and peripheral monocytes induced osteoclastogenesis. The number of TRAP-positive multinucleated cells was reduced when activated CD4+ T cells were treated with R-125224. We established a new animal model for monitoring osteoclastogenesis, SCID-HuRAg-pit. We found that with R-125224 treatment, the number of pits formed on the implanted dentin slices was significantly reduced and the number of lymphocytes in the implanted RA synovial tissue was dramatically reduced in this model. CONCLUSION This is the first study to demonstrate the suppressive effect of anti-human Fas mAb on osteoclastogenesis in RA synovial tissues through the induction of T cell apoptosis. Induction of apoptosis of infiltrated lymphocytes could be a useful therapeutic strategy for RA, in terms of suppressing both inflammation and bone destruction.

[1]  A. Wunder,et al.  Synovial mast cells require C5a receptor (CD88) for arthritis induction , 2003, Arthritis Research & Therapy.

[2]  S. Goldring,et al.  Pathogenesis of bone lesions in rheumatoid arthritis , 2002, Current rheumatology reports.

[3]  K. Yudoh,et al.  Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. , 2001, The Journal of rheumatology.

[4]  H. Aoki,et al.  Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. , 2001, Rheumatology.

[5]  T. Kimura,et al.  Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. , 2001, The Journal of rheumatology.

[6]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[7]  K. Nishioka,et al.  A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. , 2000, International immunology.

[8]  Kozo Nakamura,et al.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[9]  S. Goldring,et al.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. , 2000, Arthritis and rheumatism.

[10]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[11]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[12]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[13]  E. Jimi,et al.  Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.

[14]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[15]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[16]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[18]  H. Matsuno,et al.  Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. , 1998, Arthritis and rheumatism.

[19]  H. Matsuno,et al.  Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[20]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[21]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[23]  F. Emmrich,et al.  T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices? , 1997, Biochimica et biophysica acta.

[24]  J. McGee,et al.  The human osteoclast precursor circulates in the monocyte fraction. , 1996, Endocrinology.

[25]  T. Sumida,et al.  Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[26]  Y. Fujikawa,et al.  Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. , 1996, British journal of rheumatology.

[27]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[28]  T. Nakajima,et al.  Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. , 1995, Arthritis and rheumatism.

[29]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[30]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[31]  R. Duthie,et al.  Bone resorption by cells isolated from rheumatoid synovium. , 1992, Annals of the rheumatic diseases.

[32]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[33]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[34]  G. Firestein,et al.  How important are T cells in chronic rheumatoid synovitis? , 1990, Arthritis and rheumatism.

[35]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[36]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[37]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[38]  D. Woolley,et al.  Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. , 1984, Arthritis and rheumatism.

[39]  H. Luthra,et al.  Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates , 1981, The Journal of experimental medicine.